Sabin IPV is a liquid trivalent vaccine produced from Sabin poliovirus type 1, 2, and 3 strains grown on Vero cells.
This vaccine is indicated to prevent Wild Polio Virus, in the hope of completely eradicating the disease.
The vaccine is administered as three intramuscular injections on (0.5ml) Day 0, Day 30 and Day 60 respectively and a single intramuscular injection of vaccine (0.5 ml) at 18 months.
April 8, 2019, the results of this study were published in The Journal for Infectious Diseases.
This analysis revealed that the studied sIPV demonstrated an immunogenicity profile non-inferior to that of the conventional IPV, as well as a good safety profile.
The launch of the studied sIPV may contribute to the polio eradication endgame in developing countries and the sustainment of a polio-free world.
Clinical Trial NCT03526978: An Immunogenicity and Safety Study of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old Infants
- The study is a randomized, double-blind, controlled randomized, double-blind, controlled clinical trial.
- The purpose of this study is to evaluate the immunogenicity and safety of Sabin Inactivated Poliovirus Vaccine (Vero cell) manufactured by Sinovac Vaccine Technology Co., Ltd in 2-month-old infants.
- The control vaccine is a commercialized Inactivated Poliovirus Vaccine manufactured by Sanofi Pasteur company. 1200 healthy infants between 60-90 days will be randomly assigned into an experimental group or control group in the ratio 1:1.